Smoking cessation and nicotine de-addiction market size to grow by USD 24,529.75 Million: Rising adoption of online retailing remains key growth driver - Technavio
NEW YORK, Dec. 7, 2022 /PRNewswire/ -- The global smoking cessation and nicotine de-addiction market size is set to grow by USD 24,529.75 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 12.59% during the forecast period. This report provides analysis and insights to enable effective decision-making. Download A Sample Report
Smoking cessation and nicotine de-addiction market - Key Driver and Major Challenge
The rising adoption of online retailing is driving the smoking cessation and nicotine de-addiction market growth. The rise in the number of internet users across the world has led to an increase in the average amount of money spent online. This coupled with changing buying patterns of consumers has significantly contributed to the growth of online retailing. To capitalize on this trend, vendors are focusing on increasing their presence online. Also, there has been an increase in the number of online pharmacies and drug stores that offer nicotine patches and other NRT products. All these factors are expected to drive the growth of the global smoking cessation and nicotine de-addiction market during the forecast period.
The health issues associated with smoking cessation products is impeding the smoking cessation and nicotine de-addiction market growth. Long-term use of nicotine products can cause health issues such as hair loss, skin irritation, high blood pressure, irregular heartbeat, nausea, and others. Also, people who regularly consume nicotine products face problems with teeth and jaw because of continuous chewing. Other side effects include skin irritation, itching, dizziness, and headache. Moreover, researchers have found that two primary ingredients found in e-cigarettes are toxic to cells in the human body. Many such health risks associated with the consumption of smoking cessation products are reducing the growth potential in the market.
Technavio has identified key trends, drivers, and challenges, along with competitive analysis to help clients improve their strategies to stay ahead of their competitors. Buy the reportto obtain detailed insights about the market.
Major Five Smoking cessation and nicotine de-addiction - Companies
Alchem International Pvt. Ltd. - The company offers smoking cessation and nicotine de-addiction such as Nicotine patches, Nicotine gums, and Nicotine lozenges.
Alkalon AS - The company offers smoking cessation and nicotine de-addiction such as Nicotine Chewing Gum.
Alvogen - The company offers smoking cessation and nicotine de-addiction such as Levothyroxine Sodium Tablets.
British American Tobacco Plc - The company offers smoking cessation and nicotine de-addiction under its Velo brand and the product name is Modern Oral Products (MOPs).
Cipla Ltd. - The company offers smoking cessation and nicotine de-addiction such as NICOGUM 2 Chewing Gum, and NICOGUM 4 Chewing Gum.
Smoking Cessation and Nicotine De-addiction Market Distribution Channel Outlook (Revenue, USD mn, 2022-2027)
Drug stores and retailers - size and forecast 2022-2027
Hospital pharmacies - size and forecast 2022-2027
Online retail - size and forecast 2022-2027
Smoking Cessation and Nicotine De-addiction Market Product Outlook (Revenue, USD mn, 2022-2027)
E-cigarette - size and forecast 2022-2027
NRT - size and forecast 2022-2027
Drug therapy - size and forecast 2022-2027
Smoking Cessation and Nicotine De-addiction Market Geography Outlook (Revenue, USD mn, 2022-2027)
North America - size and forecast 2022-2027
Europe - size and forecast 2022-2027
Asia - size and forecast 2022-2027
Rest of World (ROW) - size and forecast 2022-2027
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
What are the key data covered in this smoking cessation and nicotine de-addiction market report?
CAGR of the market during the forecast period 2023-2027
Detailed information on factors that will drive the growth of the smoking cessation and nicotine de-addiction market between 2023 and 2027
Precise estimation of the smoking cessation and nicotine de-addiction market size and its contribution to the parent market.
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the smoking cessation and nicotine de-addiction industry across North America, Europe, Asia, and the Rest of the World (ROW)
A thorough analysis of the market's competitive landscape and detailed information about vendors
Comprehensive details of factors that will challenge the growth of the market vendors
Related Reports
The nicotine patch market size is predicted to surge to USD 363.81 million from 2021 to 2026 at a CAGR of 7.55%. The benefits of using nicotine patches are notably driving the nicotine patch market growth, although factors such as stringent regulations may impede the market growth.
The bronchitis treatment market size is expected to increase by USD 1.12 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.76%. The increasing prevalence of smoking is notably driving the bronchitis treatment market growth, although factors such as the high cost of healthcare may impede the market growth.
Smoking Cessation and Nicotine De-addiction Market Scope
Report Coverage
Details
Page number
167
Base year
2022
Historic period
2017-2021
Forecast period
2023-2027
Growth momentum & CAGR
Accelerate at a CAGR of 12.59%
Market growth 2023-2027
USD 24529.75 million
Market structure
Fragmented
YoY growth 2022-2023 (%)
12.4
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 32%
Key countries
US, Canada, Germany, UK, China, and India
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Alchem International Pvt. Ltd., Alkalon AS, Alvogen, Axcentria Pharmaceuticals, British American Tobacco Plc, Cambrex Corp., CHEMNOVATIC Sp. z o.o. Sp. k, Cipla Ltd., Dr Reddys Laboratories Ltd., Enorama Pharma AB, Imperial Brands Plc, Japan Tobacco Inc., Johnson and Johnson, Lil Drug Store Products Inc., Perrigo Co. Plc, Pfizer Inc., Philip Morris International, Qnovia, Tvape, and Walgreen Co.
Market dynamics
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of contents:
1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary ? Chart on Market Overview
Exhibit 02: Executive Summary ? Data Table on Market Overview
Exhibit 03: Executive Summary ? Chart on Global Market Characteristics
Exhibit 04: Executive Summary ? Chart on Market by Geography
Exhibit 05: Executive Summary ? Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary ? Chart on Market Segmentation by Product
Exhibit 07: Executive Summary ? Chart on Incremental Growth
Exhibit 08: Executive Summary ? Data Table on Incremental Growth
Exhibit 09: Executive Summary ? Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global smoking cessation and nicotine de-addiction market 2017 - 2021
Exhibit 18: Historic Market Size ? Data Table on Global smoking cessation and nicotine de-addiction market 2017 - 2021 ($ million)
4.2 Distribution channel Segment Analysis 2017 - 2021
Exhibit 45: Data Table on Online retail - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 46: Market opportunity by Distribution Channel ($ million)
7 Market Segmentation by Product
7.1 Market segments
Exhibit 47: Chart on Product - Market share 2022-2027 (%)
Exhibit 48: Data Table on Product - Market share 2022-2027 (%)
7.2 Comparison by Product
Exhibit 49: Chart on Comparison by Product
Exhibit 50: Data Table on Comparison by Product
7.3 E-cigarette - Market size and forecast 2022-2027
Exhibit 51: Chart on E-cigarette - Market size and forecast 2022-2027 ($ million)
Exhibit 52: Data Table on E-cigarette - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Chart on E-cigarette - Year-over-year growth 2022-2027 (%)
Exhibit 54: Data Table on E-cigarette - Year-over-year growth 2022-2027 (%)
7.4 NRT - Market size and forecast 2022-2027
Exhibit 55: Chart on NRT - Market size and forecast 2022-2027 ($ million)
Exhibit 56: Data Table on NRT - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Chart on NRT - Year-over-year growth 2022-2027 (%)
Exhibit 58: Data Table on NRT - Year-over-year growth 2022-2027 (%)
7.5 Drug therapy - Market size and forecast 2022-2027
Exhibit 59: Chart on Drug therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 60: Data Table on Drug therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Chart on Drug therapy - Year-over-year growth 2022-2027 (%)
Exhibit 62: Data Table on Drug therapy - Year-over-year growth 2022-2027 (%)
7.6 Market opportunity by Product
Exhibit 63: Market opportunity by Product ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 65: Chart on Market share by geography 2022-2027 (%)
Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 67: Chart on Geographic comparison
Exhibit 68: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 89: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 91: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 93: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 94: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 95: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 Canada - Market size and forecast 2022-2027
Exhibit 97: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 98: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 99: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 100: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.11 India - Market size and forecast 2022-2027
Exhibit 101: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibit 102: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibit 103: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibit 104: Data Table on India - Year-over-year growth 2022-2027 (%)
9.12 UK - Market size and forecast 2022-2027
Exhibit 105: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 106: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 107: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 108: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.13 Market opportunity by geography
Exhibit 109: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 110: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 112: Overview on factors of disruption
11.4 Industry risks
Exhibit 113: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 114: Vendors covered
12.2 Market positioning of vendors
Exhibit 115: Matrix on vendor position and classification
12.3 Alchem International Pvt. Ltd.
Exhibit 116: Alchem International Pvt. Ltd. - Overview
Exhibit 117: Alchem International Pvt. Ltd. - Product / Service
Exhibit 118: Alchem International Pvt. Ltd. - Key offerings
12.4 Alkalon AS
Exhibit 119: Alkalon AS - Overview
Exhibit 120: Alkalon AS - Product / Service
Exhibit 121: Alkalon AS - Key offerings
12.5 Alvogen
Exhibit 122: Alvogen - Overview
Exhibit 123: Alvogen - Product / Service
Exhibit 124: Alvogen - Key offerings
12.6 British American Tobacco Plc
Exhibit 125: British American Tobacco Plc - Overview
Exhibit 126: British American Tobacco Plc - Business segments
Exhibit 127: British American Tobacco Plc - Key news
Exhibit 128: British American Tobacco Plc - Key offerings
Exhibit 129: British American Tobacco Plc - Segment focus
12.7 Cambrex Corp.
Exhibit 130: Cambrex Corp. - Overview
Exhibit 131: Cambrex Corp. - Product / Service
Exhibit 132: Cambrex Corp. - Key news
Exhibit 133: Cambrex Corp. - Key offerings
12.8 Cipla Ltd.
Exhibit 134: Cipla Ltd. - Overview
Exhibit 135: Cipla Ltd. - Business segments
Exhibit 136: Cipla Ltd. - Key news
Exhibit 137: Cipla Ltd. - Key offerings
Exhibit 138: Cipla Ltd. - Segment focus
12.9 Dr Reddys Laboratories Ltd.
Exhibit 139: Dr Reddys Laboratories Ltd. - Overview
Exhibit 140: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 141: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 142: Dr Reddys Laboratories Ltd. - Segment focus
12.10 Enorama Pharma AB
Exhibit 143: Enorama Pharma AB - Overview
Exhibit 144: Enorama Pharma AB - Product / Service
Exhibit 145: Enorama Pharma AB - Key news
Exhibit 146: Enorama Pharma AB - Key offerings
12.11 Imperial Brands Plc
Exhibit 147: Imperial Brands Plc - Overview
Exhibit 148: Imperial Brands Plc - Business segments
Exhibit 149: Imperial Brands Plc - Key news
Exhibit 150: Imperial Brands Plc - Key offerings
Exhibit 151: Imperial Brands Plc - Segment focus
12.12 Japan Tobacco Inc.
Exhibit 152: Japan Tobacco Inc. - Overview
Exhibit 153: Japan Tobacco Inc. - Business segments
Exhibit 154: Japan Tobacco Inc. - Key news
Exhibit 155: Japan Tobacco Inc. - Key offerings
Exhibit 156: Japan Tobacco Inc. - Segment focus
12.13 Johnson and Johnson
Exhibit 157: Johnson and Johnson - Overview
Exhibit 158: Johnson and Johnson - Business segments
Exhibit 159: Johnson and Johnson - Key news
Exhibit 160: Johnson and Johnson - Key offerings
Exhibit 161: Johnson and Johnson - Segment focus
12.14 Perrigo Co. Plc
Exhibit 162: Perrigo Co. Plc - Overview
Exhibit 163: Perrigo Co. Plc - Business segments
Exhibit 164: Perrigo Co. Plc - Key news
Exhibit 165: Perrigo Co. Plc - Key offerings
Exhibit 166: Perrigo Co. Plc - Segment focus
12.15 Pfizer Inc.
Exhibit 167: Pfizer Inc. - Overview
Exhibit 168: Pfizer Inc. - Product / Service
Exhibit 169: Pfizer Inc. - Key news
Exhibit 170: Pfizer Inc. - Key offerings
12.16 Philip Morris International
Exhibit 171: Philip Morris International - Overview
Exhibit 172: Philip Morris International - Business segments
Exhibit 173: Philip Morris International - Key offerings
Exhibit 174: Philip Morris International - Segment focus
12.17 Tvape
Exhibit 175: Tvape - Overview
Exhibit 176: Tvape - Product / Service
Exhibit 177: Tvape - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 178: Inclusions checklist
Exhibit 179: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 180: Currency conversion rates for US$
13.4 Research methodology
Exhibit 181: Research methodology
Exhibit 182: Validation techniques employed for market sizing
Exhibit 183: Information sources
13.5 List of abbreviations
Exhibit 184: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.
CancerVision and...